13F Holdings
中文EN

TCRG Cannaisseur Group Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1879270 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY78.2%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-162,372.1%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets2,151,675.0%
Debt / equity—
Current ratio0.00x
Interest coverage-403.02x

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-116,771.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$0$700$53,130$88,145
Cost of revenue$910$4,275$26,976$42,839
Gross profit-$910-$3,575$26,154$45,306
SG&A expense$1.72M$1.26M$216,054$137,207
Operating income-$1.72M-$1.27M-$189,900-$91,901
Interest expense$4,277$6,427$1,654$2,112
Pretax income-$1.81M-$1.27M-$172,586-$94,013
Income tax$0$0$0$0
Net income-$1.77M-$1.27M-$128,025-$80,147
EBITDA—-$1.27M-$186,078-$87,643
EPS (basic)-0.03-0.030.000.00
EPS (diluted)-0.03-0.030.000.00
Weighted avg. shares (diluted)53.90M43.81M39.70M36.17M
Balance sheet
Cash & equivalents$22$563$38,390$18,534
Receivables$0$285$0$807
Inventory$118$1,028$5,303$13,456
Current assets$140$1,876$43,693$35,797
PP&E, net——$0$3,822
Total assets$140$1,876$43,693$59,289
Current liabilities$210,632$229,113$70,904$55,934
Short-term debt——$6,377$1,517
Long-term debt——$65,783$25,783
Total debt——$72,160$27,300
Total liabilities$235,431$305,576$136,687$81,717
Shareholders' equity-$92,889-$233,639-$26,501-$496
Net debt——$33,770$8,766
Shares outstanding60.46M44.34M42.55M37.20M
Cash flow statement
Operating cash flow-$127,451-$110,627-$126,074-$23,935
Financing cash flow$126,910$72,800$145,930$36,445
Depreciation & amortization—$0$3,822$4,258
Stock-based compensation$1.29M$1.04M$0—

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.